Ryckelynck J P, Chouraqui D, Lobbedez T
Service de néphrologie-dialyse-transplantation rénale, CHU Clémenceau, Caen.
Nephrologie. 1998;19(4):223-5.
Continuous or intermittent use of unfractioned heparin is the anticoagulant of choice to prevent the extracorporeal circulation clotting during the hemodialysis session. However, low molecular weight heparin (LMVH) could be an alternative treatment especially in case of high risk bleeding or during some clinical conditions such as diabetes mellitus, cerebrovascular bleeding, malignant hypertension. LMVH may be given as a single initial bolus injection generally adequate. Heparinization must be lowered or stopped when an effective anticoagulation is previously used.
持续或间断使用普通肝素是预防血液透析过程中体外循环凝血的首选抗凝剂。然而,低分子量肝素(LMVH)可能是一种替代治疗方法,尤其是在高出血风险或某些临床情况下,如糖尿病、脑血管出血、恶性高血压。低分子量肝素通常单次静脉推注即可。如果之前已进行有效抗凝,则必须降低或停止肝素化。